The Hyperphagia Questionnaire (HQ), a 13-item caregiver-reported questionnaire has limitations when compared with industry measures. To overcome these limitations, a research team developed and validated the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) for use in Prader-Willi Syndrome (PWS) clinical trials. The HQ-CT was designed to assess hyperphagia-related behaviors in patients with PWS, ages 13 to 65 years, and their caregivers. The HQ-CT was developed using a 10-item preliminary HQ-CT, which was revised and reduced to a 9-item version. The HQ-CT was designed to be self-administered by the primary caregiver of the PWS patient. The HQ-CT was validated using rigorous methods, including item-total correlations and inter-item correlations, and is considered the gold standard for the assessment of hyperphagia-related behaviors in PWS clinical trials. The validation process included a comprehensive review of the item content, and item modifications were made to improve the reliability and validity of the measure. The HQ-CT was designed to be responsive to changes in hyperphagia-related behaviors, and the psychometric properties of the HQ-CT were evaluated using item response theory. The HQ-CT was found to be a valid and reliable tool for assessing hyperphagia-related behaviors in PWS patients and their caregivers.